NCT00171015CompletedPhase 3
An Open,Multicenter Study to Evaluate the Efficacy and Safety of a 4 Week Therapy With Valsartan/Hydrochlorothiazide 160/25 (Fixed Dose Combination of Valsartan 160 mg Plus HCTZ 25 mg) in Patients Not Adequately Responding to a 4 Week Monotherapy With Olmesartan Medoxomil 40 mg or Combination Therapy With Olmesartan Medoxomil 20 mg Plus HCTZ 12.5 mg
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Novartis
- Enrollment
- 212
- Locations
- 2
- Primary Endpoint
- Change from baseline in diastolic blood pressure after 4 weeks
Study Overview
Brief Summary
To evaluate the efficacy of valsartan 160 mg/HCTZ 25 mg in patients not adequately responding to monotherapy with olmesartan medoxomil 40 mg or combination therapy with olmesartan medoxomil 20 mg plus HCTZ 12.5 mg by testing the hypothesis that valsartan 160 mg/HCTZ 25 mg significantly reduces the trough mean sitting diastolic blood pressure (MSDBP) after a 4-week treatment in the nonresponder population.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Females must be either post-menopausal for one year, surgically sterile or using effective contraceptive methods (e.g. barrier method with spermicide, intra-uterine device, hormonal contraceptives).
- •Patients with essential hypertension:
- •At Visit 1, untreated patients should have a MSDBP >100 mmHg and < 110 mmHg and treated patients need to have a MSDBP < 110 mmHg. Untreated patients can be included as soon as the safety laboratory parameters are available, but not at the day of Visit
- •This inclusion visit will be recorded as Visit 3 in the CRF.
- •At Visit 2, patients previously treated for hypertension need to have a MSDBP ≥ 100 mmHg and < 110 mmHg for entrance into the first treatment phase. Patients previously treated for hypertension who have a MSDBP < 100 mmHg at Visit 2 will continue the wash-out phase and will be again evaluated with regard to BP criteria at Visit
- •Untreated patients do not perform Visit
- •At Visit 3, which is not performed for patients who entered the first treatment phase already at Visit 2, patients need to have a MSDBP >100 mmHg and < 110 mmHg for entrance into the first treatment phase.
- •At Visit 4, all patients need to have a MSDBP >90 mmHg for entrance into the second treatment phase.
Exclusion Criteria
- •MSDBP >110 mmHg or MSSBP >180 mmHg
- •Pregnant or nursing women
- •Inability to completely discontinue all antihypertensive medications safely for a period of up to 2 weeks, as required by the protocol
- •Other protocol-defined exclusion criteria may apply.
Outcomes
Primary Outcomes
Change from baseline in diastolic blood pressure after 4 weeks
Secondary Outcomes
- Diastolic blood pressure less than 90 mmHg or decrease in diastolic blood pressure of 10 mmHg or greater after 4 weeks
- Change from baseline in systolic blood pressure after 4 weeks
- Diastolic blood pressure less than 90 mmHg after 4 weeks
- Change from baseline heart rate after 4 weeks
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 3
VALID: Study to Compare the Reduction of Predialysis Systolic Blood Pressure With Valsartan Compared to Irbesartan in Patients With Mild to Moderate Hypertension on Long-term HemodialysisHypertensionNCT00171080Novartis86
Completed
Phase 4
Efficacy and Safety of Valsartan, Hydrochlorothiazide and Amlodipine Combination Therapy in HypertensionHypertensionNCT00400777Novartis460
Completed
Phase 4
To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes MellitusProteinuriaMicroalbuminuriaNCT00550095Novartis509
Completed
Phase 3
Valsartan/Hydrochlorothiazide Combination in the Treatment of Severe HypertensionHypertensionNCT00273299Novartis607
Completed
Phase 4
Prevention of CHOP-induced Chronic CardiotoxicityNon-Hodgkin's LymphomaNCT00162955Osaka City University150